Sunstone Life Science Ventures Fund IV announces first close
Sunstone Life Science Ventures today announced the first closing of its Sunstone Life Science Ventures Fund IV (“Sunstone LSV IV”) at €80 million.
The investment strategy of the new fund is a continuation of Sunstone’s successful strategy of investing in novel therapeutics with the potential to improve the quality of patient care and treatment.
The typical investments are based on strong science and technology with innovative products addressing unmet medical needs within the framework of an attractive business case.
Press inquiries should be adressed to: